Point-of-care pancreatic stone protein measurement in critically ill COVID-19 patients
© 2023. The Author(s)..
INTRODUCTION: Pancreatic stone protein (PSP) is a novel biomarker that is reported to be increased in pneumonia and acute conditions. The primary aim of this study was to prospectively study plasma levels of PSP in a COVID-19 intensive care unit (ICU) population to determine how well PSP performed as a marker of mortality in comparison to other plasma biomarkers, such as C reactive protein (CRP) and procalcitonin (PCT).
METHODS: We collected clinical data and blood samples from COVID-19 ICU patients at the time of admission (T0), 72 h later (T1), five days later (T2), and finally, seven days later. The PSP plasma level was measured with a point-of-care system; PCT and CRP levels were measured simultaneously with laboratory tests. The inclusion criteria were being a critical COVID-19 ICU patient requiring ventilatory mechanical assistance.
RESULTS: We enrolled 21 patients and evaluated 80 blood samples; we found an increase in PSP plasma levels according to mixed model analysis over time (p < 0.001), with higher levels found in the nonsurvivor population (p < 0.001). Plasma PSP levels achieved a statistically significant result in terms of the AUROC, with a value higher than 0.7 at T0, T1, T2, and T3. The overall AUROC of PSP was 0.8271 (CI (0.73-0.93), p < 0.001). These results were not observed for CRP and PCT.
CONCLUSION: These first results suggest the potential advantages of monitoring PSP plasma levels through point-of-care technology, which could be useful in the absence of a specific COVID-19 biomarker. Additional data are needed to confirm these results.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
BMC anesthesiology - 23(2023), 1 vom: 30. Juni, Seite 226 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Melegari, Gabriele [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9007-41-4 |
|---|
| Anmerkungen: |
Date Completed 03.07.2023 Date Revised 19.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12871-023-02187-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358929644 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358929644 | ||
| 003 | DE-627 | ||
| 005 | 20231226075803.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12871-023-02187-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM358929644 | ||
| 035 | |a (NLM)37391718 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Melegari, Gabriele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Point-of-care pancreatic stone protein measurement in critically ill COVID-19 patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.07.2023 | ||
| 500 | |a Date Revised 19.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a INTRODUCTION: Pancreatic stone protein (PSP) is a novel biomarker that is reported to be increased in pneumonia and acute conditions. The primary aim of this study was to prospectively study plasma levels of PSP in a COVID-19 intensive care unit (ICU) population to determine how well PSP performed as a marker of mortality in comparison to other plasma biomarkers, such as C reactive protein (CRP) and procalcitonin (PCT) | ||
| 520 | |a METHODS: We collected clinical data and blood samples from COVID-19 ICU patients at the time of admission (T0), 72 h later (T1), five days later (T2), and finally, seven days later. The PSP plasma level was measured with a point-of-care system; PCT and CRP levels were measured simultaneously with laboratory tests. The inclusion criteria were being a critical COVID-19 ICU patient requiring ventilatory mechanical assistance | ||
| 520 | |a RESULTS: We enrolled 21 patients and evaluated 80 blood samples; we found an increase in PSP plasma levels according to mixed model analysis over time (p < 0.001), with higher levels found in the nonsurvivor population (p < 0.001). Plasma PSP levels achieved a statistically significant result in terms of the AUROC, with a value higher than 0.7 at T0, T1, T2, and T3. The overall AUROC of PSP was 0.8271 (CI (0.73-0.93), p < 0.001). These results were not observed for CRP and PCT | ||
| 520 | |a CONCLUSION: These first results suggest the potential advantages of monitoring PSP plasma levels through point-of-care technology, which could be useful in the absence of a specific COVID-19 biomarker. Additional data are needed to confirm these results | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19-ICU patients | |
| 650 | 4 | |a Mortality predictor | |
| 650 | 4 | |a Pancreatic Stone Protein | |
| 650 | 7 | |a Lithostathine |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 650 | 7 | |a Procalcitonin |2 NLM | |
| 700 | 1 | |a Giuliani, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Di Pietro, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Alberti, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Campitiello, Mattia |e verfasserin |4 aut | |
| 700 | 1 | |a Bertellini, Elisabetta |e verfasserin |4 aut | |
| 700 | 0 | |a Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Barbieri, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Rosa, Alessandra |e investigator |4 oth | |
| 700 | 1 | |a Pioda, Arianna |e investigator |4 oth | |
| 700 | 1 | |a Battaglia, Paolo |e investigator |4 oth | |
| 700 | 1 | |a Quarto, Maddalena |e investigator |4 oth | |
| 700 | 1 | |a Ferri, Enrico |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t BMC anesthesiology |d 2001 |g 23(2023), 1 vom: 30. Juni, Seite 226 |w (DE-627)NLM116144939 |x 1471-2253 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:30 |g month:06 |g pages:226 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12871-023-02187-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 30 |c 06 |h 226 | ||